US2016317495A1PendingUtilityA1

Pharmacokinetics of iontophoretic sumatriptan administration

55
Assignee: TEVA PHARMACEUTICALS INT GMBHPriority: Jun 19, 2008Filed: Jul 12, 2016Published: Nov 3, 2016
Est. expiryJun 19, 2028(~1.9 yrs left)· nominal 20-yr term from priority
Inventors:Terri SebreeMark PierceCarol O'Neill
A61P 25/06A61P 1/08A61K 9/0009A61N 1/303A61N 1/30A61K 31/4045A61K 9/7023A61N 1/325A61N 1/0428
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.

Claims

exact text as granted — not AI-modified
1 . A method for treating a sumatriptan responsive state in a subject, comprising iontophoretically administering to said subject an amount of a sumatriptan using a current of 3.5 mA or greater for at least a portion of the treatment period, such that said sumatriptan responsive state in said subject is treated. 
     
     
         2 - 60 . (canceled)

Join the waitlist — get patent alerts

Track US2016317495A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.